# Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma

> **NCT00691236** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Tata Memorial Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Osteosarcoma

## Interventions

- **DRUG:** Zoledronic acid
- **DRUG:** Standard chemotherapy

## Key facts

- **NCT ID:** NCT00691236
- **Lead sponsor:** Tata Memorial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-05
- **Primary completion:** 2013-05
- **Final completion:** 2013-08
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2011-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00691236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00691236, "Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00691236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*